Table 1 Demographics of individuals undergoing DTC genetic testing

From: False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care

Characteristic N (%)
Gender
 Male 4 (8.2%)
 Female 45 (91.8%)
Age at testing
 Under 20 0 (0.0%)
 20–29 8 (16.3%)
 30–39 12 (24.5%)
 40–49 14 (28.6%)
 50–59 4 (8.2%)
 60–69 9 (18.3%)
 70 and older 2 (4.1%)
Ethnicity
 Asian 1 (2.0%)
 African American 1 (2.0%)
 Ashkenazi Jewish 15 (30.6%)
 Caucasian 25 (51.1%)
 Hispanic 1 (2.0%)
 Other/Unknown 6 (12.2%)
Proband clinical history
 Affected 12 (24.5%)
 Unaffected 36 (73.5%)
 No information provided 1 (2.0%)
Ordering provider
 Primary care physician 2 (4.1%)
 OB/GYN 4 (8.2%)
 RN/NP 5 (10.2%)
 Oncologist 10 (20.4%)
 Surgeon 2 (4.1%)
 MD geneticist/genetic counselor 20 (40.8%)
 Other 6 (12.2%)
Test(s) ordered
 Single-site analysis (SSA) 22 (44.9%)
 Single-gene test (SGT) 13 (26.5%)
 Multigene panel testing (MGPT) 10 (20.4%)
 Combination of SSA/SGT/MGPT 4 (8.2%)
Disease gene analyzed
 Cancer 43 (87.8%)
 Connective-tissue disorder 1 (2.0%)
 Cystic fibrosis 4 (8.2%)
 Familial Mediterranean fever 1 (2.0%)
Source of DTC results
 DTC report/raw data provided 13 (26.5%)
 Results transcribed on test requisition form or in clinic note 26 (53.1%)
 Third-party data interpretation service 10 (20.4%)
  1. DTC, direct to consumer.